Capecitabine
Bile Duct Carcinoma
University of WashingtonSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Bile Duct Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1 | CC |
Elimusertib National Cancer Institute (NCI) | Phase 1 | CC |
Ropidoxuridine National Cancer Institute (NCI) | Phase 1 | CC |
cgx1321 Curegenix Inc. | Phase 1 | CC |
177lu-dota-sna040 SmartNuclide Biopharma | Early Phase 1 | C |
View all 16 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →